Nationwide Fund Advisors boosted its stake in shares of PRA Health Sciences Inc. (NASDAQ:PRAH) by 90.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,336 shares of the company’s stock after buying an additional 14,370 shares during the period. Nationwide Fund Advisors’ holdings in PRA Health Sciences were worth $1,714,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of PRAH. Acadian Asset Management LLC raised its stake in PRA Health Sciences by 1.0% in the third quarter. Acadian Asset Management LLC now owns 2,353,233 shares of the company’s stock valued at $132,978,000 after buying an additional 22,690 shares in the last quarter. 1st Global Advisors Inc. purchased a new stake in PRA Health Sciences during the third quarter valued at about $615,000. Fox Run Management L.L.C. purchased a new stake in PRA Health Sciences during the third quarter valued at about $243,000. Eagle Asset Management Inc. raised its stake in PRA Health Sciences by 11.4% in the third quarter. Eagle Asset Management Inc. now owns 1,075,028 shares of the company’s stock valued at $60,749,000 after buying an additional 110,085 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in PRA Health Sciences by 120.5% in the third quarter. BNP Paribas Arbitrage SA now owns 2,093 shares of the company’s stock valued at $118,000 after buying an additional 1,144 shares in the last quarter.
Shares of PRA Health Sciences Inc. (NASDAQ:PRAH) traded up 0.13% on Friday, reaching $55.06. The company had a trading volume of 170,924 shares. The firm has a market capitalization of $3.38 billion, a PE ratio of 42.75 and a beta of 0.61. PRA Health Sciences Inc. has a 12 month low of $35.60 and a 12 month high of $60.96. The company’s 50-day moving average is $54.94 and its 200 day moving average is $49.68.
PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $0.64 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.64. The business had revenue of $399.80 million for the quarter, compared to analyst estimates of $394.87 million. PRA Health Sciences had a return on equity of 21.25% and a net margin of 4.86%. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 EPS. Equities analysts forecast that PRA Health Sciences Inc. will post $2.47 earnings per share for the current year.
Several research firms recently issued reports on PRAH. TheStreet raised PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Monday, November 14th. Zacks Investment Research lowered PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, November 9th. KeyCorp reissued a “buy” rating on shares of PRA Health Sciences in a research report on Friday, November 4th. Credit Suisse Group AG reissued a “hold” rating and set a $50.00 price target on shares of PRA Health Sciences in a research report on Thursday, November 3rd. Finally, Citigroup Inc. upped their price target on PRA Health Sciences from $55.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, September 22nd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. PRA Health Sciences presently has a consensus rating of “Buy” and an average target price of $55.86.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.